Bright Minds Biosciences
DRUG | NASDAQ
$22.61
-$0.50 (-2.16%)
At close: Nov 16, 2026, 4:00 PM ET
$22.61
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-2.16%
(1D)Rating
23.5
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #958/1021 (Top 94%)
Key Statistics
Market Data
Market Cap $223.03M
1D Range
21.56 24.28
52W Range
18.96 95.99
Valuation (TTM)
PE -11.32
PB 1.03
EV/EBITDA -0.25
Valuation (NTM)
Forward PE N/A
Forward PEG -0.09
Price Target $147.50
Cash Flow
FCF Yield -7.8%
SBC Adj. FCF Yield -8.6%
SBC Impact -9.4%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y -52.6% |
28.7%
FCF 3Y | 5Y -94.8% |
-19.4%
Returns
ROA -8.0%
ROE -12.6%
ROIC -12.9%
Financial Health
Net Cash
C$308.33M ($217.21M)
Current Ratio 121.97
Interest Coverage -2,336.36
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2...
Sector Healthcare
Industry Biotechnology
Employees 26
IPO Date Mar 22, 2021
Website www.brightmindsbio.com
Fiscal Year October - September
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
5
Consensus
Buy
Price Target
$147.50
Upside
+552.37%
Buy (5)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove DRUG